Atlas Capital Advisors Inc. Purchases Shares of 2,844 Biogen Inc. $BIIB

Atlas Capital Advisors Inc. acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, HoldingsChannel reports. The fund acquired 2,844 shares of the biotechnology company’s stock, valued at approximately $501,000.

Several other institutional investors also recently modified their holdings of the company. Caprock Group LLC bought a new position in Biogen during the third quarter worth $742,000. Generali Investments Management Co LLC raised its position in shares of Biogen by 408.2% in the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after purchasing an additional 8,008 shares during the period. SG Americas Securities LLC raised its position in shares of Biogen by 1,793.8% in the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock valued at $32,352,000 after purchasing an additional 174,122 shares during the period. TD Asset Management Inc lifted its stake in shares of Biogen by 12.7% during the 3rd quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock worth $22,580,000 after buying an additional 18,168 shares during the last quarter. Finally, K.J. Harrison & Partners Inc acquired a new stake in shares of Biogen during the 3rd quarter worth about $1,553,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

BIIB opened at $198.64 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97. The firm has a market cap of $29.33 billion, a P/E ratio of 21.31 and a beta of 0.20. The business’s fifty day moving average is $189.16 and its 200-day moving average is $184.48.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the business posted $3.02 earnings per share. Biogen’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Analysts Set New Price Targets

BIIB has been the topic of a number of research reports. Mizuho decreased their price target on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research note on Monday. Citigroup raised their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Sanford C. Bernstein reduced their price objective on Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. Evercore assumed coverage on Biogen in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. Finally, Morgan Stanley lifted their price target on Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $216.70.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.